Transmedics panel defies expectations
A scorchingly positive adcom was somewhat unexpected given the FDA’s scepticism in the briefing documents.
Floating medtechs go big or go home
IPOs in the medical device sector are bigger than in biotech, but performance, at least of the biggest groups, is mixed.
Medtech gears up for a vintage acquisition year
Device deal making is back in a big way, despite the munificence of venture funds.
Medtech venture funding hits new heights
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
Smaller medtechs suffer, but not from Covid-19
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
Role reversal for large-cap medtechs
Shareholders are rewarding the kinds of companies they punished a year ago.
